NCT03723603

Brief Summary

Patients who meet the inclusion criteria will be provided with fibrillar collagen powder dressing. The powder dressing will be used in accordance with its label. After cleansing the wound by the clinical site staff, the powder is placed directly on the wound, and then the wound will be covered with an appropriate moisture retentive secondary dressing. Patients will visit the clinic twice a week to have the powder re-applied. Wound evaluations will take place once a week at the outpatient clinic, with the intervention lasting up to twelve weeks. Concurrent standard of care, such as compression for venous ulcers, will be provided.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 25, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 29, 2018

Completed
11 days until next milestone

Study Start

First participant enrolled

November 9, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 4, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2019

Completed
8 months until next milestone

Results Posted

Study results publicly available

March 18, 2020

Completed
Last Updated

March 18, 2020

Status Verified

February 1, 2020

Enrollment Period

7 months

First QC Date

October 25, 2018

Results QC Date

February 19, 2020

Last Update Submit

March 4, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Wound Size Over Twelve Week Period

    Baseline to 84 days

Secondary Outcomes (2)

  • Change in Bates-Jensen Wound Assessment Tool

    Baseline to 84 days

  • Change in Reported Pain Level

    Baseline to 84 days

Study Arms (1)

Fibrillar Collagen Powder Dressing

EXPERIMENTAL
Device: Fibrillar collagen powder dressing

Interventions

A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.

Fibrillar Collagen Powder Dressing

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Has one of the following types of wounds below the knee: diabetic ulcers, pressure ulcers, venous ulcers, ulcers of mixed-vascular origin, traumatic wounds, or post-surgical wounds
  • Wound has been present for at least four weeks
  • Wound is free of necrotic tissue or debridement practices will take place prior to initial visit in order to remove necrotic tissue
  • Wound has failed at least one wound care treatment
  • Wound size is between 1 and 100 square centimeters
  • Patient has adequate circulation as demonstrated by biphasic or triphasic Doppler waveform, measured within three months prior to study enrollment. If monophasic on exam, then non-invasive tests must display Ankle Brachial Index greater than 0.8 and no worse than mild disease on segmental pressures.
  • Wound is confirmed as being free of infection and absence of osteomyelitis

You may not qualify if:

  • Pregnant, planning to become pregnant during the study timeframe, or breast feeding
  • Unable or unwilling to receive porcine collagen
  • Wound is infected or presence of osteomyelitis
  • Allergy or sensitivity to collagen
  • Inability, in the opinion of the Investigator to follow protocol requirements, attend follow up visits in a timely manner, or otherwise comply with the requirements of the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Foot and Ankle Clinic

Cleveland, Ohio, 44103, United States

Location

MeSH Terms

Conditions

Wounds and Injuries

Results Point of Contact

Title
Stephanie Martynenko
Organization
Medline Industries, Inc

Study Officials

  • Windy Cole

    Cleveland Foot and Ankle Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2018

First Posted

October 29, 2018

Study Start

November 9, 2018

Primary Completion

June 4, 2019

Study Completion

July 30, 2019

Last Updated

March 18, 2020

Results First Posted

March 18, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations